South Rampart Pharma
South Rampart Pharma, Inc. is a clinical-stage life science company dedicated to developing safer, non-opioid pain therapies. Their mission is to advance innovative small molecules designed to overcome the risks of current pain medicines, offering patients and clinicians safer options. Their lead asset, SRP-001, is a novel, non-addictive, non-toxic small molecule in clinical trials, with a focus on addressing the global need for safer pain medications and reducing the burden of pain management. The company is actively engaged in clinical trials, patent development, and collaborations with research institutions to bring innovative pain relief solutions to market.
Industries
Nr. of Employees
small (1-50)
South Rampart Pharma
New Orleans, Louisiana, United States, North America
Products
Lead non‑opioid small‑molecule analgesic candidate (Phase 2‑ready)
A novel non‑opioid new chemical entity developed to reduce pain and fever in preclinical models while avoiding the hepatotoxicity and nephrotoxicity associated with some current analgesics; completed Phase 1 clinical testing and positioned for Phase 2 acute pain studies.
Lead non‑opioid small‑molecule analgesic candidate (Phase 2‑ready)
A novel non‑opioid new chemical entity developed to reduce pain and fever in preclinical models while avoiding the hepatotoxicity and nephrotoxicity associated with some current analgesics; completed Phase 1 clinical testing and positioned for Phase 2 acute pain studies.
Services
Clinical development and trial sponsorship
Sponsor and manage early‑phase randomized clinical trials including safety, tolerability, and PK/PD assessments; coordinate with CRO partners and external development labs for trial conduct and clinical manufacturing.
CMC development and clinical material supply
Route scouting, process optimization, multi‑kilogram API manufacture, formulation development for oral and parenteral forms, analytical method qualification, and stability testing to support clinical programs.
Preclinical research and translational assay development
Conduct of preclinical efficacy and safety studies, mechanistic CNS investigations, metabolomic and imaging assays, and translational biomarker development to support IND‑enabling packages.
Grant and commercialization readiness support
Management and execution of NIH-funded development programs to advance preclinical and clinical work toward commercialization readiness.
Clinical development and trial sponsorship
Sponsor and manage early‑phase randomized clinical trials including safety, tolerability, and PK/PD assessments; coordinate with CRO partners and external development labs for trial conduct and clinical manufacturing.
CMC development and clinical material supply
Route scouting, process optimization, multi‑kilogram API manufacture, formulation development for oral and parenteral forms, analytical method qualification, and stability testing to support clinical programs.
Preclinical research and translational assay development
Conduct of preclinical efficacy and safety studies, mechanistic CNS investigations, metabolomic and imaging assays, and translational biomarker development to support IND‑enabling packages.
Grant and commercialization readiness support
Management and execution of NIH-funded development programs to advance preclinical and clinical work toward commercialization readiness.
Expertise Areas
- Early‑phase clinical development
- Clinical pharmacology and PK/PD analysis
- Small‑molecule medicinal chemistry and lead optimization
- Preclinical pharmacology and translational neuroscience
Key Technologies
- LC‑MS/MS metabolomics
- MALDI mass spectrometry imaging
- Spatial single‑cell transcriptomics
- In vivo analgesia and antipyresis models